Kurzfassung

BNT211-01 / 4781/0008 - Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6 positive relapsed or refractory advanced solid tumors